EFG Asset Management North America Corp. Increases Stock Position in Repligen Corporation $RGEN

EFG Asset Management North America Corp. grew its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 149.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,286 shares of the biotechnology company’s stock after acquiring an additional 19,363 shares during the quarter. EFG Asset Management North America Corp.’s holdings in Repligen were worth $4,015,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Twin Tree Management LP purchased a new position in shares of Repligen in the first quarter worth approximately $29,000. Hantz Financial Services Inc. boosted its holdings in shares of Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after buying an additional 293 shares during the last quarter. Signaturefd LLC boosted its holdings in shares of Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after buying an additional 128 shares during the last quarter. Center for Financial Planning Inc. boosted its holdings in shares of Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after buying an additional 126 shares during the last quarter. Finally, AlphaQuest LLC purchased a new position in shares of Repligen in the second quarter worth approximately $104,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insiders Place Their Bets

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on RGEN. Jefferies Financial Group set a $160.00 price objective on shares of Repligen and gave the stock a “hold” rating in a report on Tuesday, October 28th. Canaccord Genuity Group raised their price objective on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a research note on Tuesday. Barclays raised their target price on shares of Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Finally, Evercore ISI raised their target price on shares of Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $173.85.

Repligen Trading Down 2.2%

Repligen stock opened at $146.93 on Wednesday. The stock has a market cap of $8.27 billion, a P/E ratio of 7,350.18, a PEG ratio of 3.32 and a beta of 1.08. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The firm’s 50 day moving average price is $136.52 and its 200-day moving average price is $129.15.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.04. The firm had revenue of $188.80 million for the quarter, compared to analysts’ expectations of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The company’s revenue for the quarter was up 21.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.